Mostrando 10 resultados de: 11
Publisher
Bionatura(2)
Cancer Biotherapy and Radiopharmaceuticals(1)
Clinical and Translational Immunology(1)
Frontiers in Public Health(1)
Hybridoma(1)
Área temáticas
Enfermedades(11)
Farmacología y terapéutica(7)
Medicina y salud(6)
Microorganismos, hongos y algas(2)
Problemas sociales y servicios a grupos(2)
Área de conocimiento
Inmunología(5)
Cáncer(4)
Ensayo clínico(2)
Medicina interna(2)
Cuidado de la salud(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(11)
ODS 3: Salud y bienestar(11)
Origen
scopus(11)
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusNimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
ArticleAbstract: EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis.Palabras claves:brief research report nimotuzumab, covid-19, eGFR, FIBROSIS, inflammation, Monoclonal antibody, SARS-COV-2Autores:Batista D., Cabrera L., Diaz H., Domeq M., Gorte A., Hernández A., Hernández R., Jiménez J., Jova J.H., Luaces P.L.o., Martínez A., Medel L., Pérez Ruiz L., Porto L., Ramos M., Saavedra Hernández D., Sánchez L., Tania Crombet, Travieso N., Troche M., Valdés L., Valls A.R.Fuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopusShort communication: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
ArticleAbstract: High levels of growth factors and their receptors have been demonstrated in human tumors. Gliomas anPalabras claves:Autores:Figueredo R., Iznaga N., Lage Davila A., Menéndez A., Pérez R., Ramos M., Rodríguez V., Stevenson A., Tania Crombet, Torres F., Torres O., Veitía I.Fuentes:scopusQuality of life assessment as a predictor of survival in cancer
ArticleAbstract: The quality of life and survival are variables to take into account in the clinical trial of oncologPalabras claves:clinical trials, Oncology, quality of life, SurvivalAutores:Aliuska Frías, Ballesteros J., Bouza-Herrera C.N., Carmen Elena Viada, García L., Mabel Álvarez, Martha M. Fors-López, Ramos M., Santiesteban Y.Fuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopus